Marathon Capital Management’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RPRX
Marathon Capital Management's RPRX Position: Q2 2026 in Review
Marathon Capital Management increased its Royalty Pharma (RPRX) stake by 4.3% in Q2 2026, buying an estimated $20.1K and bringing the position to 9,364 shares worth $525K. The position accounts for 0.11% of the portfolio, ranked #106.
Marathon Capital Management first reported a position in RPRX in Q3 2025 and has held it in 4 quarters since. 644 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.
- Marathon Capital Management held 9,364 shares of Royalty Pharma worth $525K as of Q2 2026.
- Marathon Capital Management bought 387 Royalty Pharma shares in Q2 2026, an estimated $20.1K.
- Royalty Pharma made up 0.11% of Marathon Capital Management's portfolio in Q2 2026, its #106 holding.
- Marathon Capital Management first reported a position in Royalty Pharma in Q3 2025 and has held it in 4 quarters since.
- 644 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.
Based on Marathon Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.